Evidence-Based Treatment of Cerebrovascular Disease

Evidence-Based Use of Medical Therapy in Secondary Stroke Prevention
Abdullah Nassief, MBBS, M.D. -- Department of Neurology
Washington University School of Medicine -- Presented August 22, 2006

Introduction

The following lecture is part of an ongoing series of lectures that discuss the current state of evidence supporting different treatments for the most common types of cerebrovascular disease.

This lecture assesses the evidence about various medical therapies in secondary stroke prevention, including perindopril, eprosartan, nitrendipine, and candesartin.

All References

Table of Contents

1. Evidence-based of medical therapy in secondary stroke prevention
2. Disclosure
3. Levels of Evidence
4. Summary of presentation
5. HTN and secondary stroke prevention
6. Blood pressure and recurrent stroke risk
7.Effect of blood pressure on secondary stroke
8.Perindopril protection against secondary stroke
9. Patient eligibility
10. PROGRESS study endpoints
11. Effect on BP
12. Outcome (stroke)
13. Effects of study trdatment on stroke (table)
14. ACCESS trial
15. ACCESS trial II
16. ACCESS study design
17. Candesartan effect on BP
18. Event rate
19. Morbidity and Mortality after stroke: eprosartan vs. nitrendipine
20. Study design
21. MOSES: treatment plan
22. SBP and DBP reduction
23. Study endpoints
24. MOSES outcome
25. Statins and secondary stroke prevention
26. Mechanism of action
27. SPARCL trial
28. Baseline characteristics
29. Primary endpoint: time to fatal or non-fatal stroke
30. Endpoint: time to stroke or TIA
31. Selected secondary endpoints
32. Liver and muscle adverse events
33. Diabetes mellitus
34. Diabetes mellitus II
35. Diabetes mellitus III
36. U of Oxford Diabetes Trial Unit
37. Fatal and non-fatal stroke
38. Fatal and non-fatal myocardial infarction
39. Smoking
40. Physical inactivity
41. Diet/nutrition
42. Lowering homocysteine
43. VISP study
44. Homocysteine level in VISP study
45. Outcome in VISP study
46. HOPE 2 (homocysteine study)
47. PLasma levels of homocysteine
48. HOPE 2 outcome
49. NORVIT acute coronary syndrome study
50. Outcome